Abeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Abeona Therapeutics Inc. (Nasdaq: ABEO) has successfully raised $25 million through a registered direct offering under Nasdaq rules. The funds were primarily raised to support the launch preparations for the Company's EB-101 Biologics License Application (BLA) submission and potential approval. Abeona entered into definitive agreements with existing institutional investors, issuing and selling 3..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 4.
  • textsms

Auxilius Pharma Raises Seed Round of $1 Million and Commences its Clinical Program

Auxilius Pharma has raised $1 million in seed funding to develop its lead asset, AUX-001, a new medication for treating chronic-stable angina pectoris in the US. The company is developing the drug as there have been very few medications developed to address chest pain symptoms suffered by patients with underlying coronary artery disease. Auxilius plans to conduct a first-in-human exploratory pha..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 20.
  • textsms